Larimar Therapeutics, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Larimar submitted a rolling Biologics License Application (BLA) to the FDA seeking accelerated approval of nomlabofusp for Friedreich's ataxia (FA) in adults and pediatric patients, using skin frataxin (FXN) as a novel surrogate endpoint. The company has $128.7M in cash (runway into late Q2 2027), reported Q3 2026 net loss of $31.1M ($0.29/share), and projects potential U.S. approval in mid-2027 with Q3 2027 launch if approved; Phase 3 FORWARD-FA trial continues enrolling.
Why this rating
Major regulatory milestone (BLA submission) for lead asset in ~$95M company; material funding cushion; multiple near-term catalysts (FDA acceptance, approval, launch) over next 12 months; high execution risk on approval and commercialization.
Tradability signal
NO TRADE
No trade: already up 12.9% on the news and the fade evidence is too weak. Similar past filings (508 in this cell) moved -0.04% in the called direction over 4 hrs; shrunk for sample size that's a -0.04% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $2.90 ▼ 5.35% | at our read · unknown $3.06 | +10 min · unknown $3.26 ▲ 6.40% | +30 min · unknown $3.07 ▲ 0.26% | +1 hr · unknown $3.10 ▲ 1.01% | +4 hrs · unknown $2.90 ▼ 5.52% |
The stock had already moved +5.66% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.